FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1799226444> ?p ?o ?g. }

• W1799226444 endingPage "1913" @default.
• W1799226444 startingPage "1907" @default.
• W1799226444 abstract "Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T cell-replete HLA-mismatched HSCT and may also benefit myeloablative conditioning (MAC) transplants. We conducted a phase II trial of short-course bortezomib plus standard tacrolimus/methotrexate after busulfan/fludarabine MAC in 34 patients with predominantly myeloid malignancies. Fourteen (41%) received 8/8 HLA-matched unrelated donor (MUD) and 20 (59%) received 7/8 HLA-mismatched related/unrelated donor peripheral blood stem cell grafts. Median age was 49 years (range, 21 to 60), and median follow-up was 25 months (range, 11 to 36). The regimen was well tolerated. No dose modifications were required. Neutrophil and platelet engraftment occurred at a median of 14 (range, 10 to 33) and 17 (range, 10 to 54) days, respectively. Median 30-day donor chimerism was 99% (range, 90 to 100), and 100-day grades II to IV and III to IV acute GVHD incidence was 32% and 12% respectively. One-year chronic GVHD incidence was 50%. Two-year cumulative incidence of both NRM and relapse was 16%. Two-year progression-free and overall survival rates were 70% and 71%, respectively. Outcomes were comparable to an 8/8 MUD MAC cohort (n = 45). Immune reconstitution was robust. Bortezomib-based MAC HSCT is well tolerated, with HLA-mismatched outcomes comparable with 8/8 MUD MAC HSCT, and is suitable for randomized evaluation. (clinicaltrials.gov: NCT01323920.)." @default.
• W1799226444 created "2016-06-24" @default.
• W1799226444 creator A5001407163 @default.
• W1799226444 creator A5008718116 @default.
• W1799226444 creator A5011648025 @default.
• W1799226444 creator A5017958702 @default.
• W1799226444 creator A5029278364 @default.
• W1799226444 creator A5029390145 @default.
• W1799226444 creator A5031812464 @default.
• W1799226444 creator A5045479163 @default.
• W1799226444 creator A5054037976 @default.
• W1799226444 creator A5058268746 @default.
• W1799226444 creator A5060510354 @default.
• W1799226444 creator A5066824630 @default.
• W1799226444 creator A5068050082 @default.
• W1799226444 creator A5069157171 @default.
• W1799226444 creator A5074589634 @default.
• W1799226444 creator A5079056163 @default.
• W1799226444 date "2015-11-01" @default.
• W1799226444 modified "2023-10-14" @default.
• W1799226444 title "A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial" @default.
• W1799226444 cites W1491993932 @default.
• W1799226444 cites W1968856388 @default.
• W1799226444 cites W1973248441 @default.
• W1799226444 cites W1977166918 @default.
• W1799226444 cites W1978164777 @default.
• W1799226444 cites W2009686578 @default.
• W1799226444 cites W2022664029 @default.
• W1799226444 cites W2033144445 @default.
• W1799226444 cites W2061069485 @default.
• W1799226444 cites W2068547289 @default.
• W1799226444 cites W2073140442 @default.
• W1799226444 cites W2087613277 @default.
• W1799226444 cites W2090344650 @default.
• W1799226444 cites W2091844260 @default.
• W1799226444 cites W2100411523 @default.
• W1799226444 cites W2129678556 @default.
• W1799226444 cites W2133590829 @default.
• W1799226444 cites W2135329608 @default.
• W1799226444 cites W2141557403 @default.
• W1799226444 cites W2144789671 @default.
• W1799226444 cites W2148207894 @default.
• W1799226444 doi "https://doi.org/10.1016/j.bbmt.2015.05.027" @default.
• W1799226444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4604028" @default.
• W1799226444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26055298" @default.
• W1799226444 hasPublicationYear "2015" @default.
• W1799226444 type Work @default.
• W1799226444 sameAs 1799226444 @default.
• W1799226444 citedByCount "27" @default.
• W1799226444 countsByYear W17992264442016 @default.
• W1799226444 countsByYear W17992264442017 @default.
• W1799226444 countsByYear W17992264442018 @default.
• W1799226444 countsByYear W17992264442019 @default.
• W1799226444 countsByYear W17992264442020 @default.
• W1799226444 countsByYear W17992264442021 @default.
• W1799226444 countsByYear W17992264442023 @default.
• W1799226444 crossrefType "journal-article" @default.
• W1799226444 hasAuthorship W1799226444A5001407163 @default.
• W1799226444 hasAuthorship W1799226444A5008718116 @default.
• W1799226444 hasAuthorship W1799226444A5011648025 @default.
• W1799226444 hasAuthorship W1799226444A5017958702 @default.
• W1799226444 hasAuthorship W1799226444A5029278364 @default.
• W1799226444 hasAuthorship W1799226444A5029390145 @default.
• W1799226444 hasAuthorship W1799226444A5031812464 @default.
• W1799226444 hasAuthorship W1799226444A5045479163 @default.
• W1799226444 hasAuthorship W1799226444A5054037976 @default.
• W1799226444 hasAuthorship W1799226444A5058268746 @default.
• W1799226444 hasAuthorship W1799226444A5060510354 @default.
• W1799226444 hasAuthorship W1799226444A5066824630 @default.
• W1799226444 hasAuthorship W1799226444A5068050082 @default.
• W1799226444 hasAuthorship W1799226444A5069157171 @default.
• W1799226444 hasAuthorship W1799226444A5074589634 @default.
• W1799226444 hasAuthorship W1799226444A5079056163 @default.
• W1799226444 hasBestOaLocation W17992264441 @default.
• W1799226444 hasConcept C120665830 @default.
• W1799226444 hasConcept C121332964 @default.
• W1799226444 hasConcept C126322002 @default.
• W1799226444 hasConcept C141071460 @default.
• W1799226444 hasConcept C143998085 @default.
• W1799226444 hasConcept C2776364478 @default.
• W1799226444 hasConcept C2776694085 @default.
• W1799226444 hasConcept C2776755627 @default.
• W1799226444 hasConcept C2777408962 @default.
• W1799226444 hasConcept C2777478702 @default.
• W1799226444 hasConcept C2779263901 @default.
• W1799226444 hasConcept C2779972918 @default.
• W1799226444 hasConcept C2780611847 @default.
• W1799226444 hasConcept C2781413609 @default.
• W1799226444 hasConcept C2911091166 @default.
• W1799226444 hasConcept C61511704 @default.
• W1799226444 hasConcept C71924100 @default.
• W1799226444 hasConcept C88879693 @default.
• W1799226444 hasConcept C90924648 @default.
• W1799226444 hasConceptScore W1799226444C120665830 @default.
• W1799226444 hasConceptScore W1799226444C121332964 @default.
• W1799226444 hasConceptScore W1799226444C126322002 @default.
• W1799226444 hasConceptScore W1799226444C141071460 @default.
• W1799226444 hasConceptScore W1799226444C143998085 @default.

• next